Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread -- Ignore unavailable to you. Want to Upgrade?

To: 2MAR$ who wrote (31336)	2/6/2001 9:57:40 AM
From: SirRealist	Respond to of 49816

Lexicon Genetics Grants Patented Gene Targeting Technology License to Immunex Corporation TUESDAY, FEBRUARY 06, 2001 7:00 AM - PRNewswire THE WOODLANDS, Texas, Feb 6, 2001 /PRNewswire via COMTEX/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that it has granted to Immunex Corporation (Nasdaq: IMNX) a multi-year, non-exclusive sublicense for the use of its patented gene targeting technology for Immunex's internal research programs. The sublicense applies to any Immunex product that has used the Lexicon technology since the date of patent issuance. Under the terms of the agreement, Lexicon will receive annual license fees, technology usage fees for each model developed by Immunex using Lexicon's patented gene targeting technology and milestone payments on each product that has or will benefit from the use of Lexicon's patented technology. Immunex is the 14th sublicensee of Lexicon's patented gene targeting technology. "Our agreement with Immunex demonstrates the evolution of our drug discovery platform, as well as the strength of our testing and evaluation process," said Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of Lexicon. "First, it confirms the importance of in vivo mammalian target validation for efficient drug discovery, and second, it provides further market validation of our patented process in drug discovery." Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Complementary to its gene-specific custom knockout technology, Lexicon has invented high-throughput genome-wide gene trapping technology to discover thousands of genes and expand its OmniBank(R) library of tens of thousands of knockout mouse clones. The Company uses an integrated platform of functional genomics technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. Lexicon's Internet exchange, www.lexgen.com, enables researchers worldwide to access the OmniBank library and form collaborations with Lexicon to discover pharmaceutical products based on genes and knowledge of their functions. Lexicon has established drug discovery collaborations with Abgenix, Inc. and Arena Pharmaceuticals, Inc., a LexVision(TM) collaboration with Bristol-Myers Squibb Company, and functional genomics and OmniBank alliances with many pharmaceutical and biotechnology companies, including American Home Products, Boehringer Ingelheim Pharmaceuticals, DuPont Pharmaceuticals Company, Millennium Pharmaceuticals, Inc., N.V. Organon, Pharmacia Corp., The R.W. Johnson Pharmaceutical Research Institute of Johnson & Johnson and Tularik, Inc., as well as leading academic institutions worldwide. Additional Company information is available at www.lexicon-genetics.com.